A Phase 1, Multicenter, Open Label, Dose Escalating, Safety Study of Human Umbilical Cord Blood Derived, Culture Expanded, Natural Killer Cell (PNK-007) Infusion
|Effective start/end date||12/1/15 → 12/31/20|
- Celgene Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.